DOCSLIB.ORG

ISSN 1096-7192 Volume 126 , Issue 2 , February 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ISSN 1096-7192 Volume 126 , Issue 2 , February 2019 ISSN 1096-7192 Volume 126 , Issue 2 , February 2019 Available online at www.sciencedirect.com Molecular Genetics and Metabolism 126 (2019) S1 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Program and Abstracts WORLDSymposium 2019* 15th Annual Research Meeting Hyatt Regency Orlando 9801 International Drive, Orlando, Florida, USA February 4 – 7, 2019 Organizing Committee Chester B. Whitley, PhD, MD, Chair Lalitha R. Belur, PhD** Philip J. Brooks, PhD** Amber R. Brown, CPP Brenda M. Diethelm-Okita, MPA Yoshikatsu Eto, MD, PhD** Amy Gaviglio, MS, LCGC** Stephen C. Groft, PharmD** Jeanine R. Jarnes, PharmD Priya S. Kishnani, MD, MBBS** Walter C. Low, PhD** R. Scott McIvor, PhD** Jill A. Morris, PhD** Li Ou, PhD** Anne R. Pariser, MD** Marc C. Patterson, MD** David A. Pearce, PhD** Mark S. Sands, PhD** Dawn C. Saterdalen, RN, MBA Danilo A. Tagle, PhD** Cynthia J. Tifft, MD, PhD** Tiina K. Urv, PhD** Steven U. Walkley, DVM, PhD * WORLD is the acronym for We’re Organizing Research for Lysosomal Diseases ** Special thanks is given to members of the Program Committee responsible for abstract review and scoring for platform presentation. https://doi.org/10.1016/j.ymgme.2018.12.013 Available online 29 December 2018 1096-7192 Molecular Genetics and Metabolism 126 (2019) S2–S6 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme WORLDSymposium™ 2019 Introduction Overview category of Basic Science was expanded to include 2 new subcategories: 1) Disease Mechanisms, Pathology, and Biomarkers of Lysosomal Now in the 15th year, WORLDSymposium™ is celebrating numerous Diseases, and 2) Developing Therapeutic Approaches for Lysosomal milestones in research for lysosomal diseases. WORLDSymposium is a Diseases in the Laboratory. The category of Translational Research was multidisciplinary forum and research meeting with the primary purpose subdivided into 3 areas: 1) Gene Therapy, 2) Newborn Screening, and of presenting and discussing the latest advances in basic science, 3) Clinical Trial Readiness – Preclinical Trial Methods and Studies for translational studies, and clinical applications for lysosomes and lyso- Lysosomal Diseases. Finally, Clinical Applications was expanded to somal diseases. WORLD is the acronym for We're Organizing Research for address the separate areas of 1) Clinical Trials for Registration, and 2) Lysosomal Diseases, and WORLDSymposium represents the single lar- Clinical Trials: Improving Outcomes Post-Registration. gest annual global gathering of lysosomal disease experts. WORLDSymposium™ 2019 is scheduled from February 4-7, 2019, at the Poster Sessions Hyatt Regency Orlando in Orlando, Florida, USA. After consecutive record-breaking years of attendance since 2010, attendance at the 2019 In addition to the 390 abstracts submitted before the October 1 meeting is expected to exceed 1,900 participants. deadline, every year additional ‘late breaking’ abstracts can be sub- At the start of WORLDSymposium 2019, two important meetings mitted until December 1. The late-breaking abstracts may be presented help kick-off the 15th annual meeting. On Monday, February 4, 2019, in the poster sessions, but do not appear in this issue of Molecular the Lysosomal Disease Network (LDN) Council of Patient Advocates Genetics and Metabolism, nor are they systematically reviewed for a (COPA) meets in the morning to provide patient-oriented input into the platform presentation. All accepted abstracts are assigned to a specific future of the LDN. On Monday afternoon, Emerging Trends: State-of-the- time for display and discussion during the poster sessions on Tuesday Art for Experts provides updates on the basic science, diagnosis, and and Wednesday after the general session is adjourned. Abstracts are treatment of lysosomal diseases. The content provides comprehensive distributed into two separate poster sessions. First authors with last information on lysosomal diseases, but does not overlap or replace the names from A-L will present their posters on Tuesday, February 5, scientific data being presented during WORLDSymposium™ 2019. 2019, from 4:30–6:30 PM. On Wednesday, February 6, 2019, first au- The program of new research presentations runs Tuesday through thors with last names M-Z and all late-breaking abstracts will be pre- Thursday. The first day of the program is focused on Basic Science, the sented from 4:30–6:30 PM in the Exhibit Hall. second day on Translational Research, and the third on Clinical Applications. This day-by-day progression through the three stages of Molecular Genetics and Metabolism research is a signature feature of WORLDSymposium™. The main em- phasis is to assess the mechanisms and obstacles for taking laboratory To enhance awareness of lysosomal diseases and advance research discoveries to actual treatments and options for patients. A number of designed to provide better therapies, the entire February 2019 special satellite and ancillary meetings — either directly associated with issue of Molecular Genetics and Metabolism is focused on lysosomes and WORLDSymposium™, or independently organized — will be held in lysosomal diseases. In addition to abstracts being presented, the issue is adjacent areas when the meeting is not in session. The week closes with filled with the highest quality, peer-reviewed research articles, some the Council of Research Experts (CORE) NIH-funded LDN Investigators' derived from the Lysosomal Disease Network™ (LDN) studies, and nu- Meeting, which occurs on Thursday evening, February 7, 2019. The merous other organized studies and observations not directly associated Program, and more information about the Symposium and lysosomal with the LDN. diseases, are available at www.WORLDSymposia.org. Nomenclature Platform Presentations The abstracts are minimally edited for clarity and continuity. For The platform program is derived from submitted research abstracts example, it is the editorial practice of WORLDSymposium™ to eliminate judged by a review panel to be of broadest interest, and featured pre- the term “storage” in the context of the name “lysosomal storage dis- sentations by invited speakers. Abstracts submitted at www. ease”. This practice focuses attention on the growing body of knowl- WORLDSymposia.org by the regular October 1 deadline are edge indicating that ‘storage’ may not be the primary common me- considered for platform presentation. For the 2019 program, 390 chanism of pathobiology in these conditions. While the physical scientific abstracts were submitted for consideration for the 74 accumulation of undegradable macromolecules might be important in platform presentations in 7 newly expanded categories. The overall disease manifestations such as skeletal deformation, other processes https://doi.org/10.1016/j.ymgme.2018.12.014 Available online 31 December 2018 1096-7192/ © 2018 Published by Elsevier Inc. Molecular Genetics and Metabolism 126 (2019) S2–S6 such as inflammation and regulation of cell activity through the mTOR health care practitioners who are interested in being current on recent pathway, are increasingly recognized as more critical factors in the advances in the basic science, diagnosis, and treatment of lysosomal underlying pathology. diseases. This course is taught at the postgraduate level, e.g., those with Additionally, disease names and abbreviations have been edited to a PhD, MD, PharmD, DDS, MS, MPH, etc. the original format of Victor McKusick. Although more recent additions such as those made to his Online Inheritance in Man (OMIM, www. Opening Reception and Awards OMIM.org) have accumulated newer names and acronyms from the literature, WORLDSymposium™ chooses to encourage uniformity with a Monday evening will include the recognition of 10 researchers who small number of selected, clinically and historically based, standard were selected for the 2019 WORLDSymposium™ Young Investigator names. Additionally, the choice of disease names also seeks to respect Awards. The award ceremony will occur at 5:15 PM in the Regency grammatically correct language, and to endorse a limited set of Foyer, followed by the WORLDSymposium™ Opening Reception in the abbreviations, e.g., MPS I but not MPS1-H. The possessive form of Exhibit Hall at 5:30 PM. eponyms has been eliminated, e.g., Parkinson disease is used instead of Parkinson's disease and Hurler-Scheie syndrome is used instead of Young Investigator Awards “Hurler's-Scheie's syndrome”. These editorial practices are implemented as an ongoing practice of the WORLDSymposium™ and the Lysosomal Of the abstracts submitted to the meeting for review, 24 in- Disease Network to enhance progress in the field, and are also applied vestigators-in-training who submitted an abstract in the ‘Basic in development of the Official List of Lysosomal Diseases available at Research’ category also applied for the 2019 Young Investigator Award. https://www.worldsymposia.org/official-list-of-lysosomal-diseases/ The WORLDSymposium™ Planning Committee reviewed all applications and 10 individuals were selected to receive the 2019 awards. The in- Monday, February 4, 2019 vestigators listed below are recognized with the 2019 Young Investigator Award and a scholarship in partial support of their parti- Council of Patient Advocates (COPA) WORLDFair™ cipation in the meeting: On Monday morning, WORLDSymposium™ brings together the • Rhea Ashmead, University of Victoria, Victoria, Canada Lysosomal Disease Network's Council
Load more

Recommended publications
  • Assessment Report
    21 April 2017 EMA/31226/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Brineura International non-proprietary name: cerliponase alfa Procedure No. EMEA/H/C/004065/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ..................................................................................... 6 1.2. Steps taken for the assessment of the product ........................................................ 7 2. Scientific discussion ................................................................................ 9 2.1. Problem statement ............................................................................................... 9 2.1.1. Disease or condition .......................................................................................... 9 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Biologic features, aetiology and pathogenesis ....................................................... 9 2.1.4. Clinical presentation, diagnosis and stage/prognosis ............................................ 10
    [Show full text]
  • Exploiting Toxin Internalization Receptors to Enhance Delivery of Proteins to Lysosomes for Enzyme Replacement Therapy
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.22.915298; this version posted January 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Exploiting toxin internalization receptors to enhance delivery of proteins to lysosomes for enzyme replacement therapy Seiji N. Sugiman-Marangos1, Greg L. Beilhartz1, Xiaochu Zhao2, Dongxia Zhou3, Rong Hua3,4, Peter K. Kim3,4, James M. Rini3,5, Berge A. Minassian2,6, Roman A. Melnyk1,3 1Molecular Medicine Program, The Hospital for Sick Children Research Institute, 686 Bay Street Toronto, ON, Canada, M5G 0A4; 2Department of Pediatrics, The Hospital for Sick Children Research Institute, 686 Bay Street Toronto, ON, Canada, M5G 0A4;3Department of Biochemistry, University of Toronto, Toronto, ON, 1 King's College Circle, Canada M5S1A8; 4Cell Biology Program, The Hospital for Sick Children Research Institute, 686 Bay Street Toronto, ON, Canada, M5G 0A4; 5Department of Molecular Genetics, University of Toronto, ON, 1 King's College Circle, Canada M5S1A8; 6Department of Pediatrics and Dallas Children's Medical Center, University of Texas Southwestern, Dallas, Texas, USA 75390-9063; *Corresponding author: Roman A. Melnyk Associate Professor of Biochemistry and Senior Scientist University of Toronto and The Hospital for Sick Children, 686 Bay Street, Toronto, ON M5G 0A4 416-813-7654 x328557 [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.01.22.915298; this version posted January 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses
    CNS Drugs (2019) 33:315–325 https://doi.org/10.1007/s40263-019-00620-8 LEADING ARTICLE Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses Alfried Kohlschütter1 · Angela Schulz1 · Udo Bartsch2 · Stephan Storch3 Published online: 15 March 2019 © The Author(s) 2019 Abstract The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by muta‑ tions in at least 13 diferent genes and primarily afect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epilepsy, loss of vision, motor disturbances, and early death. While various therapeutic strategies are currently being explored as treatment options for these fatal disorders, there is presently only one clinically approved drug that has been shown to efectively attenuate the progression of a specifc form of neuronal ceroid lipofuscinosis, CLN2 disease (cerliponase alfa, a lysosomal enzyme infused into the brain ventricles of patients with CLN2 disease). Therapeutic approaches for the treatment of other forms of neuronal ceroid lipofuscinosis include the administration of immunosuppressive agents to antagonize neuroinfammation associated with neurodegenera‑ tion, the use of various small molecules, stem cell therapy, and gene therapy. An important aspect of future work aimed at developing therapies for neuronal ceroid lipofuscinoses is the need for treatments that efectively attenuate neurodegenera‑ tion in both the brain and the retina.
    [Show full text]
  • Lysosomal Enzyme Tripeptidyl Peptidase 1 Plays a Role in Degradation of Beta Amyloid Fibrils
    bioRxiv preprint doi: https://doi.org/10.1101/639682; this version posted May 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Lysosomal enzyme tripeptidyl peptidase 1 plays a role in degradation of beta amyloid fibrils Abbreviated Title: TPP1 role in Aβ fibril degradation Dana Cruz1, Mukarram El-Banna2, Amitabha Majumdar1, David E. Sleat2, Michelle Muldowney1, Peter Lobel2&, Frederick R. Maxfield1& 1 Department of Biochemistry, Weill Cornell Medical College, New York, NY 10065. 2Center for Advanced Biotechnology and Medicine, Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08854. &To whom correspondence should be addressed: Frederick R. Maxfield Weill Cornell Medical College Department of Biochemistry 1300 York Avenue New York, NY 10065 Tel: (646) 962-2759 Fax: (646) 962-0519 Email: [email protected] Peter Lobel Center for Advanced Biotechnology and Medicine Rutgers University 679 Hoes Lane Piscataway, NJ 08854 Tel: (848) 445-9831 Fax: (732) 235-5083 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/639682; this version posted May 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Alzheimer’s disease (AD) is characterized by the accumulation of amyloid plaques surrounded by microglia. In cell culture, microglia internalize fibrillar β-amyloid but do not degrade it efficiently. Unactivated microglia have a relatively high lysosomal pH, which impairs the activity of lysosomal proteases.
    [Show full text]
  • Therapeutic Landscape for Batten Disease: Current Treatments and Future Prospects
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Rev Manuscript Author Neurol. Author Manuscript Author manuscript; available in PMC 2019 August 05. Published in final edited form as: Nat Rev Neurol. 2019 March ; 15(3): 161–178. doi:10.1038/s41582-019-0138-8. Therapeutic landscape for Batten disease: current treatments and future prospects Tyler B. Johnson1, Jacob T. Cain1, Katherine A. White1, Denia Ramirez-Montealegre2, David A. Pearce1,3,*, Jill M. Weimer1,3,* 1Pediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, USA. 2Cole Neuroscience Center, University of Tennessee Medical Center, Knoxville, TN, USA. 3Department of Pediatrics, Sanford School of Medicine at the University of South Dakota, Sioux Falls, SD, USA. Abstract Batten disease (also known as neuronal ceroid lipofuscinoses) constitutes a family of devastating lysosomal storage disorders that collectively represent the most common inherited paediatric neurodegenerative disorders worldwide. Batten disease can result from mutations in 1 of 13 genes. These mutations lead to a group of diseases with loosely overlapping symptoms and pathology. Phenotypically, patients with Batten disease have visual impairment and blindness, cognitive and motor decline, seizures and premature death. Pathologically, Batten disease is characterized by lysosomal accumulation of autofluorescent storage material, glial reactivity and neuronal loss. Substantial progress has been made towards the development of effective therapies and treatments for the multiple forms of Batten disease. In 2017, cerliponase alfa (Brineura), a tripeptidyl peptidase enzyme replacement therapy, became the first globally approved treatment for CLN2 Batten disease. Here, we provide an overview of the promising therapeutic avenues for Batten disease, highlighting current FDA-approved clinical trials and prospective future treatments.
    [Show full text]
  • Missense Variation in TPP1 Gene Causes Neuronal Ceroid Lipofuscinosis Type 2 in a Family from Jammu and Kashmir-India
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 29 July 2021 doi:10.20944/preprints202107.0661.v1 Missense Variation in TPP1 Gene causes Neuronal Ceroid Lipofuscinosis Type 2 in a Family from Jammu and Kashmir-India Arshia Angural1, Kalaiarasan Ponnusamy2, Diksha Langeh1,#, Mamta Kumari1,#, Akshi Spolia1, #, Ekta Rai1, Ankush Sharma3, Kamal Kishore Pandita4,*, Swarkar Sharma1,* 1Human Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Kakryal, Jammu and Kashmir, India 2School of Biotechnology, Jawaharlal Nehru University, New Delhi, India 3Senior Consultant, Department of Neurology, Shri Mata Vaishno Devi Narayana Superspeciality Hospital, Kakryal, Jammu and Kashmir, India 4Independent Researcher, Health Clinic, Swam Vihar, Muthi, Jammu, Jammu and Kashmir, India #Equal contribution *Corresponding authors: Swarkar Sharma, email: [email protected], and Kamal Kishore Pandita, email: [email protected] ABSTRACT We report diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), a rare, hereditary neurodegenerative disease of childhood, in a four and a half year old girl, the first child of non- consanguineous parents with no family history. Despite extensive efforts by the parents, her clinical condition remained undiagnosed and without management, until recently. Our published “Bottom-up Approach”, based on comprehensive and multidisciplinary clinical, pathological, radiographical and genetic evaluations, played key role in diagnosis of the disease. Detailed analyses involving Next Generation Sequencing confirmed a missense variation NC_00011.10:g.6616374C>T (NP_000382.3:p.Arg339Gln; rs765380155) in exon 8 of TPP1 gene. In silico analyses predicted it to be highly pathogenic. Further family screening (including her both unaffected parents and asymptomatic, one year old younger sister) of the identified variation through Sanger Sequencing, revealed a perfect autosomal recessive segregation in the family.
    [Show full text]
  • Emerging New Roles of the Lysosome and Neuronal Ceroid Lipofuscinoses Anil B
    Mukherjee et al. Molecular Neurodegeneration (2019) 14:4 https://doi.org/10.1186/s13024-018-0300-6 REVIEW Open Access Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses Anil B. Mukherjee1* , Abhilash P. Appu1, Tamal Sadhukhan1, Sydney Casey1, Avisek Mondal1, Zhongjian Zhang1,2 and Maria B. Bagh1* Abstract Neuronal Ceroid Lipofuscinoses (NCLs), commonly known as Batten disease, constitute a group of the most prevalent neurodegenerative lysosomal storage disorders (LSDs). Mutations in at least 13 different genes (called CLNs) cause various forms of NCLs. Clinically, the NCLs manifest early impairment of vision, progressive decline in cognitive and motor functions, seizures and a shortened lifespan. At the cellular level, all NCLs show intracellular accumulation of autofluorescent material (called ceroid) and progressive neuron loss. Despite intense studies the normal physiological functions of each of the CLN genes remain poorly understood. Consequently, the development of mechanism-based therapeutic strategies remains challenging. Endolysosomal dysfunction contributes to pathogenesis of virtually all LSDs. Studies within the past decade have drastically changed the notion that the lysosomes are merely the terminal degradative organelles. The emerging new roles of the lysosome include its central role in nutrient-dependent signal transduction regulating metabolism and cellular proliferation or quiescence. In this review, we first provide a brief overview of the endolysosomal and autophagic pathways, lysosomal acidification and endosome-lysosome and autophagosome-lysosome fusions. We emphasize the importance of these processes as their dysregulation leads to pathogenesis of many LSDs including the NCLs. We also describe what is currently known about each of the 13 CLN genes and their products and how understanding the emerging new roles of the lysosome may clarify the underlying pathogenic mechanisms of the NCLs.
    [Show full text]
  • Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofu
    www.nature.com/scientificreports OPEN Untargeted Metabolite Profling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Received: 7 June 2018 Accepted: 12 September 2018 Late Infantile Neuronal Ceroid Published: xx xx xxxx Lipofuscinosis (CLN2, Batten Disease) Miriam Sindelar1, Jonathan P. Dyke 2, Ruba S. Deeb3, Dolan Sondhi3, Stephen M. Kaminsky3, Barry E. Kosofsky4, Douglas J. Ballon2,3, Ronald G. Crystal3 & Steven S. Gross1 Late infantile neuronal ceroid lipofuscinosis (CLN2 disease) is a rare lysosomal storage disorder caused by a monogenetic defciency of tripeptidyl peptidase-1 (TPP1). Despite knowledge that lipofuscin is the hallmark disease product, the relevant TPP1 substrate and its role in neuronal physiology/pathology is unknown. We hypothesized that untargeted metabolite profling of cerebrospinal fuid (CSF) could be used as an efective tool to identify disease-associated metabolic disruptions in CLN2 disease, ofering the potential to identify biomarkers that inform on disease severity and progression. Accordingly, a mass spectrometry-based untargeted metabolite profling approach was employed to diferentiate CSF from normal vs. CLN2 defcient individuals. Of 1,433 metabolite features surveyed, 29 linearly correlated with currently employed disease severity scores. With tandem mass spectrometry 8 distinct metabolite identities were structurally confrmed based on retention time and fragmentation pattern matches, vs. standards. These putative CLN2 biomarkers include 7 acetylated species – all attenuated in CLN2 compared to controls. Because acetate is the major bioenergetic fuel for support of mitochondrial respiration, defcient acetylated species in CSF suggests a brain energy defect that may drive neurodegeneration. Targeted analysis of these metabolites in CSF of CLN2 patients ofers a powerful new approach for monitoring CLN2 disease progression and response to therapy.
    [Show full text]